Shares in Fusion Antibodies plunge by 25% on profit warning
Clinical trials firm saw revenue is now expected to be down 42% this year with earnings also coming in well below expectations
Fusion Antibodies
Fusion Antibodies makes £1.1m loss as it restructures business
Belfast biotech firm says it is repositioning company’s service offering to best serve clients
Fusion Antibodies revenues rise 14% despite Covid challenges
Belfast biotech says growth is in line with expectations
Fusion Antibodies’ CSO increases stake in company to 2.43%
Richard Buick’s 20,000 shares issued under employee share option scheme
Revenues rise but losses widen at Belfast-based Fusion
Queen’s University spin-out is focused on the monoclonal antibody therapeutics market
Revenue up 9% at Fusion Antibodies despite pandemic
Company cuts losses but increases spend in research and development in face of crisis
Fusion shares soar on news of antigens for Covid-19 tests
Northern Ireland pharma research group offering antigens on a commercial basis
Fusion Antibodies sees annual revenues rise almost 80%
Loss narrows as company expands services and introduces new technology
Fusion Antibodies sees revenues rise almost 80%
Northern Ireland contract research company says trading in first quarter has been satisfactory
Fusion Antibodies gets green light from investors for £3m rights issue
Belfast-based contract research firm secures appoval for share placing
Fusion Antibodies announces £3m share placing to help fund Covid-19 work
Company will also use funds for existing oncology work and general working capital
Covid-19 pandemic has ‘limited impact’ on Fusion Antibodies
Clients of contract research company working on solution to coronavirus outbreak
Revenues to be ‘materially ahead’ of previous year at Fusion Antibodies
Third quarter trading continued ‘favourable trends’, NI contract research company said
Fusion Antibodies sees revenue continue to grow
Commercial roll-out of services in six-month period lifts revenue
Fusion Antibodies sees full year revenues dip 19%
Record second half revenues as pharma research group grows US business
Fusion Antibodies confirms second-half pick-up in revenue
Orders and revenues rise in Belfast-based firm in final six months of financial year
Fusion Antibodies warns of weaker revenues for 2019
Contract research firm says uncertain timing of substantial orders affecting revenues
Losses at Fusion Antibodies quadruple in ‘challenging’ period
Belfast pharmaceutical company did not recommend the payment of a dividend
Fusion Antibodies reports £700,000 loss for first trading year
Belfast company says results show ‘strong organic growth’
Shares dive in NI-based clinical trials group
Fusion Antibodies warns trading has been ‘slower than anticipated’
Fusion Antibodies flags full year revenues behind expectations
Trading in second half of year underperformed first half due to IPO process
Fusion Antibodies raises £5.5m in London Stock Exchange debut
Belfast company to use funds to expand laboratory space and develop new service lines
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices